Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2018

Electronic supplementary information (ESI)

Copper complexes as prospective anticancer agents: *In vitro* and *in vivo* evaluation, selective targeting of cancer cells by DNA damage and S phase arrest

Dharmasivam Mahendiran,^a Sethu Amuthakala,^a Nattamai S. P. Bhuvanesh,^b Raju Senthil Kumar,^c and Aziz Kalilur Rahiman^{*a}

^aPost-Graduate and Research Department of Chemistry, The New College (Autonomous), Chennai 600 014, India.

^bDepartment of Chemistry, Texas A & M University, College Station, TX 77842, USA.

^cDepartment of Pharmaceutical Chemistry, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengodu 637 205, India.

*Corresponding author. Tel.: +91 44 2835 0297; Fax: +91 44 2835 2883

E-mail address: akrahmanjkr@gmail.com

Table S1 Crystal data and structure refinement of the ligand L⁴.

CCDC	1475312		
Empirical formula	C ₉ H ₁₁ N ₃ OS		
Formula weight	209.27		
Temperature (K)	150(2)		
Wavelength (Å)	0.71073		
Crystal system	Triclinic		
Space group	Pī		
	a = 6.885(3)		
$\mathbf{U}_{\mathbf{u}} := \{\mathbf{u} \in \{\mathbf{u}\} \mid \mathbf{u} \in \{\mathbf{u}\} $	b = 7.108(3)		
Unit cell (A) dimensions (*)	c = 11.230(4)		
	$\beta = 76.662(4)$		
Volume (A ³)	500.9(3)		
Z, Calculated density (Mg/m ³)	2, 1.387		
Absorption coefficient (mm ⁻¹)	0.293		
F(000)	220		
Crystal size (mm ³)	$0.25\times0.19\times0.04$		
Theta range for data collection (°)	1.910 to 27.519		
Limiting indians	$-8 \leq h \leq 8$		
Limiting indices	$-9 \le k \le 9$		
	$-14 \le l \le 13$		
Reflections collected/unique	4355/2227 [R(int) = 0.0249]		
Completeness to theta (%)	99.30		
Refinement method	Full-matrix least-squares on F ²		
Data/restraints/ parameters	2227/0/129		
Goodness-of-fit on F ²	1.049		
Final R indices [I>2sigma(I)]	R1 = 0.0382, wR2 = 0.0998		
R indices (all data)	R1 = 0.0439, wR2 = 0.1042		
Largest diff. Peak and hole (e A^{-3})	0.291 and -0.287		

Bond	Bond lengths (Å)	Bond	Bond angles (°)
S1–C9	1.7053(17)	C7-N1-N2	117.52(14)
N1–C7	1.3683(19)	C9-N2-N1	117.48(13)
N1-N2	1.286(2)	C9–N3–C10	122.62(14)
N2–C9	1.3897(19)	C2–C1–C6	117.54(15)
N3–C9	1.341(2)	C2–C1–C7	122.26(14)
N3-C10	1.320(2)	C6–C1–C7	120.20(14)
C1–C2	1.399(2)	C1–C2–C3	121.15(14)
C1–C6	1.400(2)	C4–C3–C2	120.14(15)
C1–C7	1.480(2)	C3–C4–C5	119.76(15)
С2–С3	1.383(2)	C4–C5–C6	119.63(14)
С3–С4	1.390(2)	C5–C6–C1	121.75(15)
C4–C5	1.390(2)	N1-C7-C1	115.28(14)
С5–С6	1.380(2)	N1-C7-C8	124.54(15)
С7–С8	1.496(2)	C1–C7–C8	120.18(14)
_	_	N3-C9-N2	117.30(14)
_	_	N3-C9-S1	122.56(12)
	_	N2-C9-S1	120.14(12)

Table S2 Selected bond lengths (Å) and bond angles (°) of the ligand L^4 .

D–H···A	D–H	Н…А	D…A	D–H…A
O(1)–H(1)S(1) (i)	0.84	2.41	3.247(2)	177.3
N(2)-H(2)S(1) (ii)	0.88	2.79	3.516(2)	140.6
N(3)–H(3A)O(1) (iii)	0.88	2.20	2.953(2)	143.2
N(3)–H(3B)S(1) (iv)	0.88	2.56	3.415(2)	165.3
C(8)–H(8A)S1 (ii)	0.98	2.87	3.682(2)	140.0

Table S3 Hydrogen bond geometry of the ligand L^4 [Å and °].

Symmetry code: (i) x, y, z+1 (ii) -x+1, -y, -z (iii) -x+1, -y+1, -z+1 (iv) -x, -y+1, -z.

 Table S4 B3LYP/LANL2DZ Bond lengths (Å) and bond angles (°) of complexes (1–6).

Bond lengths								
	1 2 2 4 5	6	Experimental					
	1	2	5	т	5	0	[15, 16]	
Cu1–S1	2.213	2.219	2.212	2.211	2.217	2.210	2.211 (11)	
Cu1–S2	2.219	2.226	2.221	2.236	2.231	2.229	2.221 (12)	
Cu1–Cl1	2.309	2.301	2.305	2.312	2.303	2.301	2.303 (12)	
Bond angles								
S2–Cu1–S1	119.42	120.33	121.09	121.78	122.01	121.12	121.61	
S2–Cu1–Cl1	116.47	117.28	116.76	118.03	117.95	118.69	118.33	
S1Cu1Cl1	122.35	121.34	121.04	120.73	121.51	120.29	120.01	

	Final Intermolecular Energy (kcal/mol)			_ Final Total		Unbound	Estimated Free
Complexes	vdW + H bond + dissolving energy	Electrostatic Energy	Total (1)	Internal Energy (2) (kcal/mol)	Torsional Free Energy (3) (kcal/mol)	System's Energy (4) (kcal/mol)	Energy of Binding [(1)+(2)+(3)-(4)] (kcal/mol)
1	-5.84	-0.26	-6.10	-0.19	+1.09	-0.33	-4.87
2	-6.96	-0.97	-7.93	-0.32	+1.29	-0.44	-6.52
3	-6.82	-0.88	-7.70	-0.54	+1.62	-0.65	-5.97
4	-6.02	-0.74	-6.76	-0.28	+1.14	-0.36	-5.54
5	-4.67	-0.81	-5.48	-0.36	+1.28	-0.48	-4.08
6	-5.19	-0.27	-5.46	-0.49	+1.55	-0.47	-3.93

 Table S5 Molecular docking parameters of the copper(I) complexes (1–6) with DNA.

	Final In	termolecular E (kcal/mol)	nergy		Torsional Free Energy (3) (kcal/mol)	Unbound System's Energy (4) (kcal/mol)	Estimated Free Energy of Binding [(1)+(2)+(3)–(4)] (kcal/mol)
Complexes	vdW + H bond + dissolving energy	Electrostatic Energy	Total (1)	Final Total Internal Energy (2) (kcal/mol)			
1	-8.10	-0.16	-8.26	-1.26	-1.62	+3.29	-6.08
2	-11.35	-0.05	-11.40	-0.05	+3.84	+0.33	-7.94
3	-9.45	-0.36	-9.81	-0.36	+3.84	+0.15	-6.47
4	-8.35	-0.17	-8.52`	-1.54	+3.291	-0.47	-6.29
5	-8.15	+0.08	-8.06	-0.79	+3.29	+0.24	-5.06
6	-8.11	-0.16	-8.27	-0.34	+3.84	-0.46	-5.01

 Table S6 Molecular docking parameters of the copper(I) complexes (1–6) with focal adhesion kinase (FAK) receptor.



Fig. S1. FT IR spectra of ligand L^2 (a) and copper(I) complex 2 (b).



Fig. S2. ESI mass spectrum of complex 1.



Fig. S3. ESI mass spectrum of complex 3.



Fig. S4. ESI mass spectrum of complex 6.



Fig. S5. UV-Vis absorption spectra of the copper(I) complexes 1–3.



Fig. S6. ¹H NMR spectra of ligand L^1 (a) and complex 1 (b).



-2 Chemical Shift (ppm) -1

Fig. S7. ¹H NMR spectra of ligand L^2 (a) and complex 2 (b).







Fig. S8. N2–H2···S1, N3–H3B···S1 and C8–H8A···S1 intermolecular interaction generating $R_2^2(8)$ ring motif (a), N3–H3A···O1 intermolecular interaction generating $R_2^2(22)$ ring motif viewed down '*a*' axis (b), the intermolecular O1–H1···S1 hydrogen bonds forming a C(11) chain running along '*c*' axis (c) and π – π stacking interactions (d) for the ligand L⁴.



Fig. S9. Stability of copper(I) complexes 1 (a), 2 (b) and 3 (c) measured by UV-Vis spectroscopy.



Fig. S10. Molecular docking view of complex **1** with DNA (PDB ID: 1BNA) dodecamer duplex of sequence d(CGCGAATTCGCG)₂.



Fig. S11. Scar bar diagram of complexes (1–3) for 24 h.



Fig. S12. ROS generation in EAC cells exposed to copper(I) complexes 1–3 for 24 h.



Fig. S13. Percentage expression levels of Bcl-2, Bcl-x and Bax (a). Percentage expression levels of caspase 3/9 and cytochrome c (b); The percentage values are those relative to the control.